Olivia Vizier

Not long ago, someone asked Lawrence Blatt, Ph.D., the probability that one of his company’s drugs would be successful. “I don’t want to think about that,” responded the CEO of Aligos Therapeutics. Blatt wasn’t trying to be coy; he knew the answer, and he knew it wouldn’t sound good.

Chiasma’s Mycapssa (octreotide) has become the first FDA-approved oral therapy to treat acromegaly, a rare disorder in which overproduction of human growth hormone leads to abnormal enlargement of patients’ extremities and internal organs, the drugmaker said.

Dr. Soon-Shiong tells PEOPLE he’s working to create a more universal cancer treatment by rethinking how we use radiation to target cancer cells – and that Reid is proof it can work. Instead of blasting the body with high doses of radiation, the doctor says the method he’s testing “tickles” the cancer cells to wake

This precise approach “makes it possible to make drugs that only act on the cell type you care about,” reducing the unwanted side effects that most drugs have, says Margus, chief executive officer of Cerevance, a Boston-based drug development company focused on brain diseases. What’s more, it could lead to a major breakthrough in the

Dr. Jonathan Javitt, the CEO of NeuroRx, said, “We’re talking to people who have critical COVID-19, with respiratory failure. That is people whose lungs have been affected by the COVID virus, such that their lungs don’t send oxygen properly to their bodies. Then the drug will be available at every hospital.”

“It’s a chronic neurodegenerative process. Chronic just means it goes on very slowly over a long period of time,” said Friedlander, of NeuBase Therapeutics. Holder’s father is at the point in his diagnosis where he often forgets a pandemic is going on. Seeing people in masks scares him.

Redhill Biopharma Ltd.’s chief operating officer, Gilead Raday, told BioWorld that the firm will build on positive results in severe COVID-19 patients with oral opaganib, a first-in-class sphingosine kinase-2 inhibitor that the company has branded Yeliva, and could seek emergency use authorization based on data due by year-end.

9 Meters Biopharma’s program for celiac disease is among the most clinically advanced programs in development. With phase III trials underway and Fast Track designation from the FDA, “It’s, conservatively, at least one year ahead of everyone else’s,” John Temperato, president and CEO, told BioSpace.

It’s early days for Cue Biopharma’s CUE-101, the lead candidate in its IL-2-based CUE-100 Series. In pre-clinical studies, CUE-101 has demonstrated selective binding and preferential activation and expansion of antigen-specific T cells, dose-dependent effector cytokine production, and inhibition of tumor growth both as a monotherapy and in combination with a PD-1 inhibitor. Its first in-human

Despite being most at risk from Covid-19, older people and those with compromised immune systems are unlikely to reap much benefit from Covid-19 vaccines, which are the main way we can overcome the viral pandemic. US-based Heat Biologics believes it has the answer to give extra protection to those with less robust immune systems.

Cidara Therapeutics (NASDAQ:CDTX) is developing what may be the first antifungal to be approved in 15 years for both the treatment and prevention of invasive fungal disease.

When Karen Jackson founded Sisters Network INC. in 1994, a national African American breast cancer survivorship organization, she was optimistic to the point of wearing rose-colored glasses about the healthcare industry. She believed that if someone was sick then there would be someone to help.Your Content Goes Here

Dr. Patrick Soon-Shiong is a physician, surgeon, researcher, philanthropist, and owner of the LA Times. From 1997–2010, he served as Founder, Chairman and CEO of American Pharmaceutical Partners (APP) and Abraxis BioScience, where he developed the drug Abraxane, which received FDA approval for the treatment of metastatic breast cancer, lung cancer, and advanced pancreatic cancer. In 2008, he

Efficacy, safety, and convenience are hard-to-achieve attributes of cancer therapies, despite the best marketing engines in biopharma. Acepodia—a clinical-stage biotech focused on developing novel, targeted, allogeneic-cell based immunotherapies to treat cancers—has the gall to add affordable to the list of product attributes it’s striving for.

Harry M. Reid has a message for these incredibly bleak times: Keep fighting. Last summer the former Senate majority leader hid from the obvious fact that pancreatic cancer was on the verge of defeating him. “I wasn’t willing to acknowledge that I was about to get hit by the Grim Reaper,” Reid (D-Nev.) said Thursday

The scientist whose unorthodox approach helped former Senate Majority Leader Harry Reid beat pancreatic cancer is turning his attention toward fighting coronavirus. Dr. Patrick Soon-Shiong, who said his company ImmunityBio is working with the Department of Health and Human Services on a coronavirus vaccine, said the same treatment that worked on Reid’s cancer could be used to fight infectious diseases.

With deep roots in diabetes, this small company is pushing forward with a trial against a rare diosease known as congenital hyperinsulinism.

Mark Revord will never know for sure whether an experimental drug, known at the time as CM4620-IE, saved him from having a breathing tube inserted down his throat to manage his COVID-19 symptoms.

Fauci is “cautiously optimistic” that with multiple vaccine candidates being developed using different platforms, we’ll eventually have an effective COVID-19 vaccine. However, Dr. Patrick Soon-Shiong, CEO of biotech companies ImmunityBio and NantKwest, says the big question is the duration of immunity produced by a vaccine.

Non-invasive imaging has played an increasing role in drug discovery and development processes. Nikki Withers spoke with Yochi Slonim, who discusses a novel technology that leverages FRET signals for the discovery of small molecule drugs that selectively control mRNA translation in a novel target space.

CalciMedica Inc. revealed that, in combination with low-flow oxygen therapy, Auxora reduced the proportion of patients put on ventilators by over 50 percent compared to the SOC group and improved recovery time to less than half that of the SOC patients. The open-label study consists of 26 patients enrolled while on low-flow oxygen and randomised 2:1

The era of COVID-19 has brought on some exciting developments with the types of biopharmaceutical enterprises that are developing therapies and vaccines to treat the disease. Specifically, immuno-oncology enterprises are delving into the area, as their immunotherapies can also coincide with mechanisms of action that can also treat COVID. In this interview, Lori McDermott, VP,

Nonalcoholic steatohepatitis is a severe form of fatty liver disease that affects 3% to 5% of the population in the United States and currently no approved drugs are available for treatment, according to a press release from Durect Corporation.

Vaccinex’s Phase 2 SIGNAL study, evaluating the investigational antibody pepinemab (VX15/2503) in Huntington’s disease patients with late prodromal and early disease, is ongoing and has tested pepinemab in all 265 patients enrolled in cohort B, the company announced.

Australian drug developer Recce Pharmaceuticals has announced new data showing significant in-vivo antibacterial activity in mice treated with its lead compound RECCE 327 against Neisseria gonorrhoeae, the second most common sexually transmitted infection (STI). RECCE 327 is among a new class of synthetic antibiotics with broad-spectrum activity developed for the treatment of blood infections and sepsis derived from E. coli and S. aureus bacteria,